MEA Acute Respiratory Distress Syndrome (ARDS) Treatment Market

TABLE OF CONTENTS

1 INTRODUCTION 19

• 1.1 OBJECTIVES OF THE STUDY 19
• 1.2 MARKET DEFINITION 19
• 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 19
• 1.4 LIMITATIONS 21
• 1.5 MARKETS COVERED 21

2 MARKET SEGMENTATION 23

• 2.1 MARKETS COVERED 23
• 2.2 GEOGRAPHICAL SCOPE 24
• 2.3 YEARS CONSIDERED FOR THE STUDY 25
• 2.4 CURRENCY AND PRICING 25
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 26
• 2.6 MULTIVARIATE MODELLING 29
• 2.7 TYPE LIFELINE CURVE 29
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
• 2.9 DBMR MARKET POSITION GRID 31
• 2.10 MARKET END USER COVERAGE GRID 32
• 2.11 VENDOR SHARE ANALYSIS 33
• 2.12 SECONDARY SOURCES 34
• 2.13 ASSUMPTIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 38

• 4.1 PESTEL ANALYSIS 39
• 4.2 PORTER'S FIVE FORCES 40
• 4.3 INSURANCE REIMBURSEMENT 41
  • 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 41
  • 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 41
  • 4.3.3 ABBOTT CODING GUIDE FOR ECMO 42
  • 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 42
  • 4.3.5 CERN HEALTH INSURANCE SCHEME 43
  • 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 43
  • 4.3.7 AMERICAN HOSPITAL ASSOCIATION 44
• 4.4 PIPELINE ANALYSIS 45
• 4.5 PRICING ANALYSIS 47

5 MARKET OVERVIEW 48

• 5.1 DRIVERS 50
  • 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 50
  • 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 50
  • 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 51
  • 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 51
• 5.2 RESTRAINTS 52
  • 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 52
  • 5.2.2 HIGH COST OF DEVICES AND TREATMENT 52
• 5.3 OPPORTUNITIES 53
  • 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 53
  • 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 53
  • 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 54
• 5.4 CHALLENGES 55
  • 5.4.1 STRINGENT RULES & REGULATIONS 55
  • 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 56

6 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 57

• 6.1 OVERVIEW 58
• 6.2 MECHANICAL VENTILATION 61
  • 6.2.1 HIGH-FLOW NASAL O2 62
  • 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 62
  • 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 62
  • 6.2.4 PRONE POSITION VENTILATION 62
  • 6.2.5 OTHERS 63
• 6.3 CORTICOSTEROIDS 63
  • 6.3.1 METHYLPREDNISOLONE 64
  • 6.3.2 DEXAMETHASONE 64
  • 6.3.3 OTHERS 64
• 6.4 ANTIVIRAL MEDICATION 65
  • 6.4.1 RIBAVIRIN 66
  • 6.4.2 OSELTAMIVIR 66
  • 6.4.3 OTHERS 66
• 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 66
• 6.6 TOCILIZUMAB 67
• 6.7 OTHERS 67

7 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 68

• 7.1 OVERVIEW 69
• 7.2 SEPSIS 72
• 7.3 INHALATION OF HARMFUL SUBSTANCES 72
• 7.4 SEVERE PNEUMONIA 73
• 7.5 OTHERS 73

8 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 74

• 8.1 OVERVIEW 75
• 8.2 PARENTERAL 78
  • 8.2.1 INTRAVENOUS 78
  • 8.2.2 INTRAMUSCULAR 78
• 8.3 ORAL 79
• 8.4 OTHERS 79

9 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 80

• 9.1 OVERVIEW 81
• 9.2 HOSPITALS 84
• 9.3 SPECIALTY CLINICS 84
• 9.4 HOME HEALTHCARE 85
• 9.5 OTHERS 85

10 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 86

• 10.1 OVERVIEW 87
• 10.2 DIRECT TENDER 90
• 10.3 HOSPITAL PHARMACY 90
• 10.4 RETAIL PHARMACY 91
• 10.5 ONLINE PHARMACY 91

11 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 92

• 11.1 MIDDLE EAST AND AFRICA 94
  • 11.1.1 SOUTH AFRICA 99
  • 11.1.2 SAUDI ARABIA 104
  • 11.1.3 U.A.E 109
  • 11.1.4 ISRAEL 114
  • 11.1.5 EGYPT 119
  • 11.1.6 KUWAIT 124
  • 11.1.7 REST OF MIDDLE EAST AND AFRICA 129

12 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 130

• 12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 130

13 SWOT ANALYSIS 131

14 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 132

• 14.1 GILEAD SCIENCES INC. 132
  • 14.1.1 COMPANY SNAPSHOT 132
  • 14.1.2 REVENUE ANALYSIS 133
  • 14.1.3 COMPANY SHARE ANALYSIS 133
  • 14.1.4 PRODUCT PORTFOLIO 134
  • 14.1.5 RECENT DEVELOPMENT 134
• 14.2 TERUMO CORPORATION 135
  • 14.2.1 COMPANY SNAPSHOT 135
  • 14.2.2 REVENUE ANALYSIS 135
  • 14.2.3 COMPANY SHARE ANALYSIS 136
  • 14.2.4 PRODUCT PORTFOLIO 136
  • 14.2.5 RECENT DEVELOPMENT 136
• 14.3 GETINGE 137
  • 14.3.1 COMPANY SNAPSHOT 137
  • 14.3.2 REVENUE ANALYSIS 137
  • 14.3.3 COMPANY SHARE ANALYSIS 138
  • 14.3.4 PRODUCT PORTFOLIO 138
  • 14.3.5 RECENT DEVELOPMENT 138
• 14.4 LIVANOVA PLC 139
  • 14.4.1 COMPANY SNAPSHOT 139
  • 14.4.2 REVENUE ANALYSIS 139
  • 14.4.3 COMPANY SHARE ANALYSIS 140
  • 14.4.4 PRODUCT PORTFOLIO 140
  • 14.4.5 RECENT DEVELOPMENTS 140
• 14.5 MEDTRONIC 141
  • 14.5.1 COMPANY SNAPSHOT 141
  • 14.5.2 REVENUE ANALYSIS 141
  • 14.5.3 COMPANY SHARE ANALYSIS 142
  • 14.5.4 PRODUCT PORTFOLIO 142
  • 14.5.5 RECENT DEVELOPMENTS 142
• 14.6 ARMSTRONG MEDICAL 143
  • 14.6.1 COMPANY SNAPSHOT 143
  • 14.6.2 PRODUCT PORTFOLIO 143
  • 14.6.3 RECENT DEVELOPMENT 143
• 14.7 BESMED HEALTH BUSINESS CORP. 144
  • 14.7.1 COMPANY SNAPSHOT 144
  • 14.7.2 PRODUCT PORTFOLIO 144
  • 14.7.3 RECENT DEVELOPMENTS 145
• 14.8 DRAGERWERK AG & CO. KGAA 146
  • 14.8.1 COMPANY SNAPSHOT 146
  • 14.8.2 REVENUE ANALYSIS 146
  • 14.8.3 PRODUCT PORTFOLIO 147
  • 14.8.4 RECENT DEVELOPMENTS 147
• 14.9 EUROSETS 148
  • 14.9.1 COMPANY SNAPSHOT 148
  • 14.9.2 PRODUCT PORTFOLIO 148
  • 14.9.3 RECENT DEVELOPMENT 148
• 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 149
  • 14.10.1 COMPANY SNAPSHOT 149
  • 14.10.2 REVENUE ANALYSIS 149
  • 14.10.3 PRODUCT PORTFOLIO 150
  • 14.10.4 RECENT DEVELOPMENTS 150
• 14.11 FRESENIUS SE & CO. KGAA. 151
  • 14.11.1 COMPANY SNAPSHOT 151
  • 14.11.2 REVENUE ANALYSIS 151
  • 14.11.3 PRODUCT PORTFOLIO 152
  • 14.11.4 RECENT DEVELOPMENT 152
• 14.12 HAMILTON MEDICAL 153
  • 14.12.1 COMPANY SNAPSHOT 153
  • 14.12.2 PRODUCT PORTFOLIO 153
  • 14.12.3 RECENT DEVELOPMENT 153
• 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 154
  • 14.13.1 COMPANY SNAPSHOT 154
  • 14.13.2 PRODUCT PORTFOLIO 154
  • 14.13.3 RECENT DEVELOPMENT 154
• 14.14 NIPRO 155
  • 14.14.1 COMPANY SNAPSHOT 155
  • 14.14.2 REVENUE ANALYSIS 155
  • 14.14.3 PRODUCT PORTFOLIO 156
  • 14.14.4 RECENT DEVELOPMENT 156
• 14.15 PFIZER INC. 157
  • 14.15.1 COMPANY SNAPSHOT 157
  • 14.15.2 REVENUE ANALYSIS 157
  • 14.15.3 PRODUCT PORTFOLIO 158
  • 14.15.4 RECENT DEVELOPMENT 158
• 14.16 RESMED 159
  • 14.16.1 COMPANY SNAPSHOT 159
  • 14.16.2 REVENUE ANALYSIS 159
  • 14.16.3 PRODUCT PORTFOLIO 160
  • 14.16.4 RECENT DEVELOPMENT 160
• 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 161
  • 14.17.1 COMPANY SNAPSHOT 161
  • 14.17.2 PRODUCT PORTFOLIO 161
  • 14.17.3 RECENT DEVELOPMENT 161

15 QUESTIONNAIRE 162

16 RELATED REPORTS 165

LIST OF TABLES

• TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT 47
• TABLE 2 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 60
• TABLE 3 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
• TABLE 4 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 61
• TABLE 5 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 62
• TABLE 6 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 62
• TABLE 7 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
• TABLE 8 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 63
• TABLE 9 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 64
• TABLE 10 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 64
• TABLE 11 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
• TABLE 12 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
• TABLE 13 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 65
• TABLE 14 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 65
• TABLE 15 MIDDLE EAST AND AFRICA EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
• TABLE 16 MIDDLE EAST AND AFRICA TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
• TABLE 17 MIDDLE EAST AND AFRICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
• TABLE 18 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 71
• TABLE 19 MIDDLE EAST AND AFRICA SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
• TABLE 20 MIDDLE EAST AND AFRICA INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
• TABLE 21 MIDDLE EAST AND AFRICA SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
• TABLE 22 MIDDLE EAST AND AFRICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
• TABLE 23 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 77
• TABLE 24 MIDDLE EAST AND AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
• TABLE 25 MIDDLE EAST AND AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 78
• TABLE 26 MIDDLE EAST AND AFRICA ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
• TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
• TABLE 28 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 83
• TABLE 29 MIDDLE EAST AND AFRICA HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 84
• TABLE 30 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
• TABLE 31 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
• TABLE 32 MIDDLE EAST AND AFRICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
• TABLE 33 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 89
• TABLE 34 MIDDLE EAST AND AFRICA DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
• TABLE 35 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
• TABLE 36 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
• TABLE 37 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
• TABLE 38 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 94
• TABLE 39 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 95
• TABLE 40 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 95
• TABLE 41 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 96
• TABLE 42 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
• TABLE 43 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 96
• TABLE 44 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
• TABLE 45 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 97
• TABLE 46 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 97
• TABLE 47 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 97
• TABLE 48 MIDDLE EAST AND AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 98
• TABLE 49 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 98
• TABLE 50 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
• TABLE 51 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
• TABLE 52 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
• TABLE 53 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 100
• TABLE 54 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 100
• TABLE 55 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 100
• TABLE 56 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 101
• TABLE 57 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 101
• TABLE 58 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 59 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 101
• TABLE 60 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 102
• TABLE 61 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 102
• TABLE 62 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 102
• TABLE 63 SOUTH AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 103
• TABLE 64 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 103
• TABLE 65 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
• TABLE 66 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
• TABLE 67 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
• TABLE 68 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 105
• TABLE 69 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 105
• TABLE 70 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
• TABLE 71 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 106
• TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 106
• TABLE 73 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 74 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 106
• TABLE 75 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 107
• TABLE 76 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 107
• TABLE 77 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 107
• TABLE 78 SAUDI ARABIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 108
• TABLE 79 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 108
• TABLE 80 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 108
• TABLE 81 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
• TABLE 82 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
• TABLE 83 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 110
• TABLE 84 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 110
• TABLE 85 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
• TABLE 86 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 111
• TABLE 87 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 111
• TABLE 88 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
• TABLE 89 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 111
• TABLE 90 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 112
• TABLE 91 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 112
• TABLE 92 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 112
• TABLE 93 U.A.E PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 113
• TABLE 94 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
• TABLE 95 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
• TABLE 96 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
• TABLE 97 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
• TABLE 98 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 115
• TABLE 99 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 115
• TABLE 100 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
• TABLE 101 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 116
• TABLE 102 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 116
• TABLE 103 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
• TABLE 104 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 116
• TABLE 105 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 117
• TABLE 106 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 117
• TABLE 107 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 117
• TABLE 108 ISRAEL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 118
• TABLE 109 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 118
• TABLE 110 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
• TABLE 111 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
• TABLE 112 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
• TABLE 113 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 120
• TABLE 114 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 120
• TABLE 115 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
• TABLE 116 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 121
• TABLE 117 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 121
• TABLE 118 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
• TABLE 119 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 121
• TABLE 120 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 122
• TABLE 121 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 122
• TABLE 122 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 122
• TABLE 123 EGYPT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 123
• TABLE 124 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 123
• TABLE 125 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 123
• TABLE 126 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
• TABLE 127 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
• TABLE 128 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 125
• TABLE 129 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 125
• TABLE 130 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
• TABLE 131 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 126
• TABLE 132 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 126
• TABLE 133 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
• TABLE 134 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 126
• TABLE 135 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 127
• TABLE 136 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 127
• TABLE 137 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
• TABLE 138 KUWAIT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 128
• TABLE 139 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 128
• TABLE 140 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
• TABLE 141 REST OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129

LIST OF FIGURES

• FIGURE 1 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 23
• FIGURE 2 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION 26
• FIGURE 3 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS 27
• FIGURE 4 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 28
• FIGURE 5 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS 28
• FIGURE 6 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS 30
• FIGURE 7 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID 31
• FIGURE 8 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID 32
• FIGURE 9 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS 33
• FIGURE 10 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 37
• FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 38
• FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030 38
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 49
• FIGURE 14 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022 58
• FIGURE 15 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 59
• FIGURE 16 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 59
• FIGURE 17 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE 60
• FIGURE 18 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022 69
• FIGURE 19 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND) 70
• FIGURE 20 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030) 70
• FIGURE 21 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE 71
• FIGURE 22 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 75
• FIGURE 23 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 76
• FIGURE 24 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 76
• FIGURE 25 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 77
• FIGURE 26 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022 81
• FIGURE 27 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 82
• FIGURE 28 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030) 82
• FIGURE 29 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE 83
• FIGURE 30 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 87
• FIGURE 31 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 88
• FIGURE 32 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 88
• FIGURE 33 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 89
• FIGURE 34 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022) 93
• FIGURE 35 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 130